Recruiting Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST NCT06735820 Conditions Atypical Neurofibroma, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fibrosarcoma, +24 more Locations Children's National Hospital — Washington D.C., District of Columbia, United States UT Southwestern Medical Center — Dallas, Texas, United States View Trial Details
Not Yet Recruiting Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma NCT07521657 Conditions Astrocytoma, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +21 more Locations Childrens of Alabama — Birmingham, Alabama, United States View Trial Details
Active, Not Recruiting MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas NCT02407405 Conditions Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
